Table 1.
Available imaging agents for rheumatoid or experimental arthritis
Tracer | Target | Developmental phase | Reference |
---|---|---|---|
General tracers |
|
|
|
18 F-fluoro-2-deoxy-D-glucose |
Glucose metabolism, inflammation |
Clinical use for detection of inflammation and cancer |
[1,35] |
99mTc-diphosphonates |
Alterations in bone metabolism, osteoblastic activity |
Clinical use for bone scanning |
[33,34] |
11C-choline |
Cell membrane synthesis, inflammation |
Clinical use for detection of prostate cancer |
[36,37] |
Trial in 10 patients with inflammatory joint disease | |||
67Ga-citrate |
Circulating blood plasma proteins and leukocytes, inflammation |
Clinical use for detection of inflammation |
[14] |
99mTc-polyclonal human immunoglobulin G |
Increase in vascular permeability, hyperemia, inflammation |
Multiple trials in patients with rheumatic disorders |
[38,39] |
99mTc-/111In-labeled leukocytes |
Influx of leukocytes into inflamed tissue |
Clinical use for infectious and inflammatory disorders |
[40] |
Multiple trials in patients with RA | |||
99mTc-RP128 |
Leukocytes (binds to receptors on neutrophils and mononuclear phagocytes) |
Trial with 10 patients with RA |
[41] |
Radiolabeled biologicals | |||
99mTc-anti-CD4 mAb |
T cells |
Case study in 1 patient with RA, trial in 6 patients with RA |
[42-45] |
99mTc-anti-CD3 mAb |
T cells |
Trials in 7 patients with RA, 2 psoriatic arthritis patients, and 38 patients with RA |
[46-48] |
123I-IL-1Ra |
Inflammation |
Trial in 4 patients with active RA |
[49] |
99mTc-anti-TNF-α |
Inflammation |
Multiple trials with patients with RA |
[2,50-52] |
Phase 3 study (NCT01590966) | |||
99mTc-/124I-anti-CD20 mAb |
B cells |
Trials in 6 patients with RA and 20 patients with chronic inflammatory autoimmune disease |
[53,54] |
Specific molecular markers | |||
99mTc-acetylated poly-(1,3)-D-galactoside |
Mononuclear phagocyte trafficking (binds CD14 and CD11b) |
Trials for tumoral, inflammatory and infectious diseases |
[55] |
Preclinical, rabbit antigen-induced arthritis | |||
99mTc-/111In-octreotide |
Endothelium activation and macrophage recruitment (binds to somatostatin receptor) |
Clinical use for detection of tumors |
[56] |
Trial in 14 patients with RA | |||
11C-(R)-PK11195 |
Monocytes and macrophages (binds to peripheral benzodiazepine receptors) |
Trials in 11 patients with RA, 6 patients with RA, and 29 patients with arthralgia |
[57,58] |
111In-E-selectin-binding peptide |
Activated vascular endothelium |
Preclinical, rat adjuvant arthritis |
[59] |
99mTc-anti-E-selectin Fab/(Fab′)2 fragment |
Activated vascular endothelium |
Trial in 26 patients with RA |
[60] |
NIR-anti-E-selectin Ab |
Activated vascular endothelium |
Preclinical, CIA, and TNF-α-induced paw edema |
[61] |
99mTc-annexin V |
Apoptosis (binds to phosphatidylserine) |
Multiple trials in cancer patients |
[62] |
Preclinical, CIA | |||
Cy5.5-anti-F4/80 |
Macrophages |
Preclinical, AIA |
[63] |
99mTc-anti-IL-6R |
Inflammation |
Preclinical, murine arthritis model |
[64] |
99mTc-folic acid (EC20) |
Activated macrophages, folate receptor |
Phase 2 study in patients with autoimmune disease (NCT00588393) |
[65-67] |
NIR2-folate |
Activated macrophages, folate receptor |
Mouse arthritis models |
[68] |
18 F-PEG-folate |
Activated macrophages, folate receptor |
Preclinical, methylated bovine serum albumin-induced arthritis |
[69] |
64Cu-/18 F-galacto-arginine-glycine-aspartic acid |
Activated macrophages, osteoclasts, endothelial cells |
Clinical use, tumor angiogenesis |
[70] |
Preclinical, osteopetrosis, and osteoporosis mouse models | |||
NIR-matrix metalloproteinase-specific probe |
Sites of matrix degradation and inflammation |
Preclinical, CIA, rat OA |
[71] |
99mTc-anti-macrophage mannose receptor | Subset of macrophages | Preclinical, CIA | [72] |
99mTc, 99mtechnetium; Ab, antibody; AIA, antigen-induced arthritis; CIA, collagen-induced arthritis; IL, interleukin; mAb, monoclonal antibody; NIR, near-infrared; OA, osteoarthritis; RA, rheumatoid arthritis; TNF-α, tumor necrosis factor-alpha.